Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Sezary Syndrome 2Pancreatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Glioma 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2

Interventions

Doxorubicin 5Specimen Handling 4Radiotherapy 4Magnetic Resonance Spectroscopy 3Biopsy 3pazopanib 2Radiation 2Nivolumab 2Ipilimumab 2Ifosfamide 2CTLA-4 Antigen 2talimogene laherparepvec 1saracatinib 1sapanisertib 1romidepsin 1peposertib 1pembrolizumab 1montanide ISA 51 1liposomal doxorubicin 1cixutumumab 1cabozantinib 1X-Rays 1Temozolomide 1Sorafenib 1Ritonavir 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Interleukin-2 1Indinavir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Histiocytoma, Malignant Fibrous × pembrolizumab × Clear all
NCT06422806 2026-05-29

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

National Cancer Institute (NCI)

Phase 3 Recruiting
365 enrolled
Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡